All In Biotech

Drug Trial Radar · NCT03038100

A Study of Atezolizumab Versus Placebo in Combination With Paclitaxel, Carboplatin, and Bevacizumab in Participants With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Phase III, Multicenter, Randomized, Study of Atezolizumab Versus Placebo Administered in Combination With Paclitaxel, Carboplatin, and Bevacizumab to Patients With Newly-Diagnosed Stage III or Stage IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Last checked: Nov 20, 2026Latest source record: Feb 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,301 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,301

Actual

Start

Mar 8, 2017

Primary completion

Feb 8, 2022

Study completion Aug 12, 2022

Sponsor

Lead sponsor
Hoffmann-La RocheRoche (Genentech) (RHHBY)
Sponsor type
Industry
Collaborators
GOG Foundation; European Network of Gynaecological Oncological Trial Groups (ENGOT)
First posted
Jan 31, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase III, global, double-blind, 2-arm randomized study designed to compare the efficacy and safety of atezolizumab + paclitaxel + carboplatin + bevacizumab versus placebo + paclitaxel + carboplatin + bevacizumab. Study participants will have Stage 3 or 4 ovarian cancer (OC), fallopian tube cancer (FTC), or primary peritoneal cancer (PPC) with macroscopic residual disease postoperatively (i.e., after primary tumor reductive surgery) or who will undergo neoadjuvant therapy followed by interval surgery.

Conditions

  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Peritoneal Neoplasms

Interventions

  • PaclitaxelDrug

    Paclitaxel 175 milligrams per square meter (mg/m\^2) IV infusion on Day 1 of each 21-day cycle

  • CarboplatinDrug

    Carboplatin at a dose to achieve a target area under the curve (AUC) of 6 milligrams per milliliter\*minute (mg/mL\*min) on Day 1 of each 21-day cycle for a total of 6 cycles

  • AtezolizumabDrug

    Atezolizumab 1200 mg IV infusion on Day 1 of each 21-day cycle

  • BevacizumabDrug

    Bevacizumab 15 milligrams per kilogram (mg/kg) IV infusion as per the schedule specified in respective arms

  • Atezolizumab PlaceboDrug

    Placebo matching to atezolizumab on Day 1 of each 21-day cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) Assessed by Investigator as Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) - Intent-to-Treat (ITT) PopulationTime frame: From randomization until disease progression or death from any cause (up to approximately 55 months)
  2. PFS Assessed by Investigator as Per RECIST v1.1 - Programmed Death-Ligand 1 (PD-L1)-Positive SubpopulationTime frame: From randomization until disease progression or death from any cause (up to approximately 55 months)
  3. Overall Survival - ITT PopulationTime frame: From randomization up to death from any cause (up to approximately 59 months)
  4. Overall Survival - PD-L1-Positive SubpopulationTime frame: From randomization up to death from any cause (up to approximately 59 months)

Locations

268 sites in 22 countries. Site status is shown where the registry gives one.

  • St. Joseph'S Hospital & Medical Center

    Phoenix, Arizona

  • Arizona Oncology Associates, PC - HAL

    Scottsdale, Arizona

  • Arizona Oncology - HOPE Wilmot

    Tucson, Arizona

  • Moores Cancer Center at UC San Diego Health

    La Jolla, California

  • LAC + USC Medical Center

    Los Angeles, California

  • UCLA - School of Medicine

    Los Angeles, California

  • Kaiser Permanente - Oakland

    Oakland, California

  • The Center for Cancer Prevention and Treatment at St.Joseph Hospital of Orange

    Orange, California

  • UC Irvine Medical Center

    Orange, California

  • Stanford University

    Palo Alto, California

  • Kaiser Permanente - Sacramento

    Roseville, California

  • Southern California Kaiser Permanente

    San Diego, California

  • California Pacific Medical Center Research Institute

    San Francisco, California

  • K. Permanente - San Fransisco

    San Francisco, California

  • University of California San Francisco Cancer Center

    San Francisco, California

  • Kaiser Permanente - Santa Clara

    Santa Clara, California

  • Olive View/Ucla Medical Center

    Sylmar, California

  • Kaiser Permanente - Walnut Creek

    Walnut Creek, California

  • University of Colorado Hospital - Anschutz Cancer Pavilion

    Aurora, Colorado

  • Danbury Hospital

    Danbury, Connecticut

  • Eastern Connecticut Hematology and Oncology Associates; (ECHO)

    Norwich, Connecticut

  • Sylvester Comprehensive Cent.

    Miami, Florida

  • Miami Cancer Institute of Baptist Health, Inc.

    Miami, Florida

  • Sarasota Memorial Health Care System; Cancer Research Program

    Sarasota, Florida

  • Women's Cancer Associates

    St. Petersburg, Florida

  • Northside Hospital

    Atlanta, Georgia

  • Northeast Georgia Medical Center; Oncology Research Dept-5C

    Gainesville, Georgia

  • Women's Cancer Center

    Honolulu, Hawaii

  • Rush University Medical Center

    Chicago, Illinois

  • Univ of Chicago

    Chicago, Illinois

  • Sudarshan K. Sharma, MD, Ltd.

    Hinsdale, Illinois

  • Parkview Research Center

    Fort Wayne, Indiana

  • St.Vincent Health System; Gynecologic Oncology

    Indianapolis, Indiana

  • University of Iowa Hospital & Clinic; Division of Hematology/Oncology

    Iowa City, Iowa

  • University of Kentucky; Gynecologic Oncology

    Lexington, Kansas

  • St. Elizabeth Edgewood; Cancer Care Center? for Account St. Elizabeth Edgewood

    Edgewood, Kentucky

  • Woman's Hospital

    Baton Rouge, Louisiana

  • Maine Medical Partners Women's Health; Gyn-Oncology

    Scarborough, Maine

  • Greater Baltimore Medical Center

    Baltimore, Maryland

  • Sinai Hospital of Baltimore

    Baltimore, Maryland

Showing 40 of 268 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.